Latest Breaking News On - Transform patient - Page 4 : comparemela.com

Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study

Global Healthcare Cybersecurity Market Forecast to 2028:

Dublin, May 24, 2023 (GLOBE NEWSWIRE) The "Global Healthcare Cybersecurity Market by Offering (Solutions and Services), Solution Type, Threat Type,.

Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis

Phase 2 study shows 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 62% relative reduction in the rate of decline in percent predicted forced vital capacity versus. | May 22, 2023

Bristol Myers Squibb Receives European Commission Approval of Sotyktu, a Once-Daily Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis

PRINCETON - Bristol Myers Squibb today announced that the European Commission has approved Sotyktu , a first-in-class, selective tyrosine kinase 2 inhibitor, for the treatment of adults with. | March 29, 2023

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

Sotyktu demonstrated superior efficacy in improving skin clearance over placebo and twice-daily Otezla® , with a well-tolerated safety profile, in the pivotal Phase 3 POETYK PSO clinical. | March 28, 2023